Results 101 to 110 of about 15,200 (191)

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Advanced Science
First‐line treatment of multiple myeloma, a prevalent blood cancer lacking a cure, using anti‐CD38 daratumumab antibody and lenalidomide is often inadequate due to relapse and severe side effects.
Yueh‐Hsiang Yu, Wei‐Ting Tian, Cédric Grauffel, Wei‐Chen Lin, Ming‐Yu Hsieh, Pei‐Wen Wu, Hui‐Ju Lee, Chi‐Jiun Peng, Pei‐Hsuan Lin, Hsing‐Mao Chu, Carmay Lim, Tse Wen Chang   +11 more
doaj   +1 more source

Real-world drug regimes for multiple myeloma in a Swiss population (2012 to 2017) : cost-outcome description [PDF]

, 2019
Blozik, Eva, Eichler, Klaus, Rapold, Ronald, Reich, Oliver, Wieser, Simon   +4 more
core   +1 more source

HASH(0x563d442697c0) [PDF]

, 2016
HASH(0x563d4416ce80)HASH ...
Grössmann, N.
core  

Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes [PDF]

Over the past few years, many new treatments have been approved for patients with multiple myeloma (MM) and these have improved outcomes like response rates and survival.
Armeni, Patrizio, Bringhen, Sara, Entrala Cerezo, Cristina, Mendes, João, Petrucci, Maria Teresa   +4 more
core   +1 more source

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. [PDF]

, 2016
Aarts-Riemens, T, de Bruijn, J, de Haart, SJ, Doshi, P, Emmelot, ME, Groen, RWJ, Holthof, L, Lokhorst, HM, Martens, ACM, Minnema, MC, Mutis, T, Noort, WA, Sasser, K, van de Donk, NWCJ, Yuan, H   +14 more
core   +3 more sources

Innovative treatments for multiple myeloma in adults who are not candidates for stem transplantation [PDF]

In the reviewed article, we evaluated the different innovative therapeutic options for the treatment of multiple myeloma in patients who are not candidates for stem cell transplantation.
Castro, Alejandra A., Gonzalez, Guillermo A., Malfavón, Dariana Z., Olivarez, Irlanda E., Perez, Mariano B. L., Santiago, Gerardo G., Torres, Melissa F., Velasco, Juan C. D., Álvarez, José S. L.   +8 more
core   +2 more sources

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model

eJHaem
Response to daratumumab in patients with relapsed/refractory multiple myeloma is heterogeneous, and a reliable biomarker of response is lacking. We aimed to develop a method that identifies response to daratumumab therapy.
Niels vanNieuwenhuijzen, Marta Cuenca, Leonie Abbink, Margot Jak, Victor Peperzak, Monique C. Minnema   +5 more
doaj   +1 more source

P183 | DELAYED DARATUMUMAB ADDITION TO LENALIDOMIDE-DEXAMETHASONE IN OLDER MULTIPLE MYELOMA PATIENTS: INSIGHTS FROM REAL-WORLD DATA

Haematologica
Introduction In patients (pts) with multiple myeloma (MM), the combination of daratumumab, lenalidomide, and dexamethasone (Dara-Rd) is a standard of care, approved both for frontline treatment of non-transplant eligible (NTE) pts and in the relapsed ...
L. Cani, A. Di Nicola, A. Evangelista, I. Delle Donne, G. Bertuglia, A. Casson, M. D’agostino, F. Gay, A. Larocca, E. Marchetti, R. Mina, S. Oliva, T. Picardi, B. Bruno, S. Bringhen, G. Benevolo   +15 more
doaj  

Daratumumab for Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allograft: A Case Report

Kidney Medicine
Despite treatment with immunosuppressive or clone-targeted chemotherapy, patients with proliferative glomerulonephritis with monoclonal immunoglobulin deposit (PGNMID) frequently progress into end-stage kidney failure, and early recurrence of PGNMID ...
Zewei Chen, Shangxi Fu, Jun Wu, Xiaoling Luo, Zhiguo Mao, Dechao Xu, Xiang Gao   +6 more
doaj   +1 more source

Oral selinexor–dexamethasone for triple-class refractory multiple myeloma [PDF]

, 2019
al., et, Vij, Ravi
core   +1 more source